Showing posts with label drug treatment. Show all posts
Showing posts with label drug treatment. Show all posts

Sunday, October 26, 2014

KET will look at how Kentucky communities are fighting back against the heroin epidemic

Heroin use is sky-rocketing in certain areas of Kentucky and many communities are fighting back with local solutions.

Host Renee Shaw and guest will share how communities are coming together to save lives, expand treatment options and prevent others from becoming addicted on the next episode of KET's "HealthThree60" program Monday, Oct. 27 at 9 p.m. ET; and Wednesday, Oct. 29 at 3 p.m ET.

KETKY will air the show on Wednesday, Oct. 29, at 3 p.m.; Thursday, Oct. 30, at 11 p.m.; and Friday, Oct. 31, at 9 a.m. All times are Eastern.

Thursday, August 7, 2014

UK professor develops nasal spray to deliver standard antidote to painkiller overdose; fast-tracked, in final clinical trials

A new lifesaving product to treat painkiller overdoses is in its final round of clinical trials at the University of Kentucky and is being fast-tracked by the U.S. Food and Drug Administration.

The product is a nasal-spray application of the anti-opoid drug naloxone, developed by Daniel Wermeling, professor in the UK College of Pharmacy, through his startup company AntiOp Inc.

Opioids are the class of pain-killing drugs that are related to morphine, including prescription drugs such as hydrocodone and oxycodone as well as illegal drugs such as heroin. Naloxone is the the standard treatment for suspected opioid overdose, according to a UK news release.

Naloxone is now administered by injection. The spray eliminates the need for needles, with a ready-to-use, single-use delivery device inserted into the nose of an overdose victim. The product delivers a consistent dose, absorbed across the nasal membranes even if the patient is not breathing.

"The goal is to make the medication available to patients at high risk of opioid overdose and to caregivers, including family members, who may lack specialized medical training," Wermeling said. "The treatment could be given in anticipation of EMS arrival, advancing the continuum of care and ultimately saving lives."

Nationwide, deaths from opioid overdose are on the rise, according to the federal Centers for Disease Control and Prevention. Kentucky, with a long history of opoid abuse, ranks third in the nation for drug overdoses, with more than 1,000 dying each year. Heroin abuse is on the rise, with 230 deaths, or 31.9 percent, of autopsied overdose deaths attributed to heroin in 2013.  This is a 60 percent increase from the previous year, according to the Kentucky Office of Drug Control Policy.

Congratulating Wermeling on his success, UK President Eli Capilouto said, "The epidemic of opioid abuse in our state presents an enormous and urgent challenge, not only for health care providers and law enforcement but also for us here at the University of Kentucky. Dr. Wermeling's project is putting a powerful new tool into the hands of those on the front line of the fight against heroin, both here in Kentucky and beyond."

Wermeling's research was supported by a three-year, $3 million grant from the National Institutes of Health through the National Institute on Drug Abuse with additional funding from the Kentucky Science and Technology Corporation. His company partnered with Reckitt Benckiser Pharmaceuticals in May to accelerate the production and worldwide marketing of the product.

Wednesday, July 2, 2014

Drug use and other behaviors, and poor support systems, make Appalachia ripe for liver-damaging hepatitis C virus

The hepatitis C virus is a growing problem in Appalachia because of "high rates of injection use, little access to intervention services and tight-knit social circles," according to research conducted by the University of Kentucky since 2008 in Perry County, Elizabeth Adams reports for UKNow.

Hepatitis C is a contagious liver disease caused by a virus, according to the federal Centers for Disease Control and Prevention. It can be either acute or chronic, and is spread primarily through contact with the blood of an infected person, which most often occurs when people share needles or other equipment to inject drugs. Most cases progress to a chronic disease, ultimately leading to liver complications and failure.

Dr. Jennifer Havens
The research, led by Jennifer Havens, an epidemiologist in UK's Center for Drug and Alcohol Research, has tracked cases of this highly infectious virus through routine testing and interviews with 500 drug users in Perry County. Most new cases have been found in people under the age of 25.

Havens hopes to learn about the "social and behavioral risk factors that contribute to the area's prevalence of hepatitis C" and use this information to develop interventions to decrease the spread of the disease, Adams writes.

"When you think about rural communities, you think of a tight knit group -- everyone knows everyone else," Havens told Adams. "And that's what is going on here. We are seeing great potential for disease transmission."

Participants in the study were interviewed about their drug use, sexual activity and social networks. They were also tested for hepatitis C, herpes simplex II and HIV, which has not yet been identified in the tested population, Adams reports. With a participation retention rate of 95 percent over five years, researchers were able to "map support networks, drug use networks and sexual networks, as well as identify systemic changes in the drug use of the community."

When the study began in 2008, nearly 43 percent of the participants had hepatitis C, with 80 percent reporting a history of injection drug use, Adams reports.There have been 94 new cases in the past five years, and 62 percent of the participants now have the virus.

Havens said Appalachian communities have the disadvantage of being isolated from drug intervention resources, such as mobile syringe exchanges, which provide users with sanitary tools such as bleach kits, to prevent transmission or "more importantly a known community location for accessing drug treatment."

The newest medication to treat or manage hepatitis C costs $90,000 for total treatment, or $1,000 per dose, which is hardly affordable or accessible to low-income and uninsured drug users, Adams writes. Only 10 percent of the Appalachian study's participants have private insurance, while two-thirds are uninsured.

Information from this research will help Havens and her researchers develop intervention programs. Participants have suggested a syringe exchange program. Havens would like to design an intervention program utilizing the existing social networks to reduce the risk of overdose through health resource information sharing, Adams notes. Havens also emphasizes the importance of "available, accessible and affordable drug treatment to curb injection drug use and the growing rates of hepatitis C."

The Centers for Disease Control and Prevention estimates 3 million Americans are infected with hepatitis C, but thousands more are unknowingly carrying the virus.